Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis

To date, therapeutic switches are performed to reduce and prevent toxicity, improve adherence, promote virological control, and save costs. Drug switches are a daily challenge in the management of people living with HIV (PLWH), especially in those with multiple comorbidities and on polypharmacy. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzitelli, Maria, Trunfio, Mattia, Putaggio, Cristina, Sasset, Lolita, Leoni, Davide, Lo Menzo, Sara, Mengato, Daniele, Cattelan, Anna Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405513/
https://www.ncbi.nlm.nih.gov/pubmed/36009370
http://dx.doi.org/10.3390/biomedicines10081823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405513/
https://www.ncbi.nlm.nih.gov/pubmed/36009370
http://dx.doi.org/10.3390/biomedicines10081823

Ejemplares similares